number of sold units: PENTALGIN (17th place) and ARBIDOL (20th place). The ranking in real terms is headed by ACTIVATED CARBON (its share is 3.6%). It should be noted that the TOP-20 by units is composed by almost 100% of “traditional” drugs, those which are sold only in Russia and former Soviet countries. Nevertheless, these drugs do not become less popular year by year primarily due to the low price and old, you can say “age-long”, prominence among consumers. 6. VITAL DRUGS At the end of December 2009 the list of vital drugs for 2010 was adopted. There were some changes compared to the previous list. This list has not yet received an unambiguous assessment by the pharmaceutical market participants. In comparison with the list of 2009 the list of vital drugs was reduced by approximately 25%. According to the Ministry of Health Care and Social Development, the “drugs with low level of clinical efficacy” as well as diagnostic tools and disinfectants were excluded from the new list. Among those excluded drugs METAMIZOLE SODIUM should be noted, known to pharmacy visitors under the brand ANALGIN. According to the monitoring results, in 2009, the drugs of 562 INNs listed in vital drugs list were sold. In 2010, 423 INNs were registered. There were 65 new INNs, 208 INNs were excluded. Compared to 2009 list, the share of domestic drugs has increased (almost 68% of names). At the same time the following drugs were excluded from the list: ALL multivitamin drugs and vitamin and mineral complexes (UNDEVIT, GEKSAVIT, COMPLIVIT, etc.), nitroxoline drugs (5NOC), certain antibiotics (LOMEFLOXACINE), antiviral drugs, in particular the drug used for prevention and treatment of influenza (RIMANTADINE), vaccines for prevention of poliomyelitis, hepatitis B, etc. New list is shorter than the previous one. ETHANOL in solution for external use, in contrast, entered the new list. The well-known ARBIDOL expanded the list by dosage forms for adults. From the anti-influenza drugs homeopathic drug ANAFERON for children was also included to the list. It should be noted that many domestic drugs were included to the list. As a result the situation in the balance of imported and domestic drugs became more similar to the market average 24% in value terms, and it was not possible to increase significantly the market share in real terms. Diagram 11 Share of domestic drugs in vital drugs list 2009
2010 38,1
54%
Average price, ruble
31,6
56%
21%
Sales volume
24%
Sales value
Source: “Monthly retail audit of the pharmaceutical market in the Russian Federation”, DSM Group. ISO 9001:2008
16